Loading
Benitec Biopharma Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SUVRETTA CAPITAL MANAGEMENT, LLC, was filed 29 Dec 2025.
Benitec Biopharma Inc.: what insiders have been doing
Benitec Biopharma Inc., classified in the Healthcare & Pharma sector, is a listed company based in Sydney, Australia, founded in 1997. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 2 insiders published 5 filings.
Only purchases show up on the open market, 4 purchases in all worth €17.9M, filed by 1 insider. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €8.8M, bought by Suvretta Capital Management, LLC and made public on 10 November 2025. On the buying side, the filings list 1 senior executive among the declarants.
The latest purchase dates back some time: it was published 293 days ago, on 29 December 2025. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 5 filings here. Looking back to 2021, when coverage begins, insiders filed 12 purchases and no sales.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
16
Thresholds
n/a
Buy Volume
€29M
12 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleSuvretta Capital Management, LLC9 buys
Since the insiders bought
- -27.8%Entry US$13.93 · Close at T+90 US$10.06
- -93.9%Entry US$54.91 · Close at T+365 US$3.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Benitec Biopharma Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$24.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended June 2026 · cache
US$8.46
Analyst consensus
6 analystsStrong buy
US$17.00Target US$24.33(+188%)US$32.00
Income statement
Gross profitUS$75k
EBITDA-US$50.7M
Net income-US$45.5M0.0% margin
Valuation
P/Book1.6x
Beta0.25
Balance sheet & cash
Market capUS$295.1M
Total debtUS$762k
Free Cash Flow-US$16.6M
Debt / Equity0%
Profitability & ownership
ROE-33.2%
ROA-22.7%
% insiders2.5%
% institutions96.1%
Last declaration on 30 June 2026
Declarations16 total
51,813 sharesCommon StockSEC:0001193125-26-290586:0
42,600 shares@ US$12.851.6% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-25-001479:0
Canonical exit: 23 Mar 2026 (T+90)
8,700 shares@ US$11.240.3% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-25-001459:0
Canonical exit: 18 Mar 2026 (T+90)
730,370 shares@ US$13.5029.2% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-25-001256:0
Canonical exit: 5 Feb 2026 (T+90)
751,111 shares@ US$13.5030.0% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-25-001256:1
Canonical exit: 5 Feb 2026 (T+90)
9,503 shares@ US$12.630.4% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-25-000486:0
Canonical exit: 29 Jun 2025 (T+90)
793,800 shares@ US$13.0032.7% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-25-000479:0
Canonical exit: 24 Jun 2025 (T+90)
103,626 shares0Common StockSEC:0001062993-25-005393:0
51,813 shares@ US$3.86100.0% of flowCommon StockSEC:0001062993-25-004077:0
24,360 shares@ US$10.980.9% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-24-001385:0
Canonical exit: 23 Mar 2025 (T+90)
37,190 shares@ US$9.601.2% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-24-001318:0
Canonical exit: 3 Mar 2025 (T+90)
12,430 shares@ US$9.730.4% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-24-001299:0
Canonical exit: 17 Feb 2025 (T+90)
588,236 shares@ US$1.92993.5% of flowCommon stock, par value $0.0001 per shareSEC:0000899140-24-001042:0
25,907 sharesCommon StockSEC:0000899243-23-018119:0
Canonical exit: 9 Nov 2023 (T+90)
51,813 sharesCommon StockSEC:0000950170-23-042536:0
Canonical exit: 9 Nov 2023 (T+90)
100,000 shares@ US$5.4486100.0% of flowCommon Stock, par value $0,0001 per shareSEC:0001104659-21-148207:0
Canonical exit: 27 Jul 2021 (T+90)
16 of 16 declarations
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (ticker: BNTC) is a U.S.-listed biotechnology company traded on the Nasdaq market in the United States. The company is best described as a clinical-stage gene therapy and genetic medicines developer, with its business centered on a proprietary DNA-directed RNA interference platform, branded as “Silence and Replace.” The scientific concept combines RNA interference with gene replacement in a single therapeutic construct, aiming to suppress disease-causing genes while simultaneously delivering a functional replacement gene. That platform-level approach is the core of Benitec’s investment case and its main differentiator versus more conventional gene-silencing or gene-replacement strategies.
Benitec has an international legacy. It was originally founded in Australia in 1995 and later redomiciled to the United States. Today, the company is headquartered in Hayward, California, which places it firmly within the U.S. biotech ecosystem while preserving a long-standing global research background. For investors, this history matters because the company has evolved from an earlier-stage scientific platform developer into a U.S.-based clinical biotechnology company, now competing for value creation through human data, regulatory milestones, and capital market execution rather than through commercial product sales.
Read moreShow less
The company’s lead program is BB-301, developed for oculopharyngeal muscular dystrophy (OPMD), a rare, progressive disease associated with swallowing impairment and limited treatment options. Benitec’s recent disclosures have highlighted encouraging interim Phase 1b/2a clinical results, durability of response, and FDA Fast Track designation for BB-301. Those updates are important because they suggest the asset is moving from pure platform story toward a more tangible clinical and regulatory narrative. In rare-disease biotech, such milestones can meaningfully change market perception, especially when the therapy targets a condition with significant unmet medical need.
From a competitive standpoint, Benitec operates in a crowded but highly specialized landscape that includes large gene therapy companies, rare-disease developers, and platform-focused biotech peers. Its relative advantage lies in the potential breadth of the ddRNAi approach and in the promise of a single administration delivering both silencing and replacement. However, as a clinical-stage company, Benitec remains dependent on trial execution, safety and efficacy data, regulatory feedback, and ongoing access to capital. That makes its financial profile typical of an early-to-mid clinical biotech: high optionality, but also high risk and dilution sensitivity.
Recent company news has been notable. In 2025, Benitec announced a roughly $100 million equity financing, a material event that improved funding visibility for ongoing development activities. The company also continued to report operational and clinical progress through 2025 and into 2026, including updates on BB-301. For U.S. equity investors following SEC Form 4 insider activity, the stock can be particularly event-driven, with trading sentiment often influenced by clinical readouts, financing announcements, and insider transactions. Overall, Benitec Biopharma Inc. is a small-cap Nasdaq biotech in the United States with a differentiated scientific platform, a rare-disease lead asset, and a risk profile that remains tightly linked to clinical and regulatory execution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
